San Francisco startup Composition Therapeutics can also be working on an oral, once-day-to-day GLP-one drug identified as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June whenever a mid-phase study confirmed ordinary weight loss of about six% and it options to start ou